857P - Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status
| Autor: | Grivas, P., Plimack, E., Balar, A.V., Castellano, D., O'Donnell, P.H., Bellmunt, J., Powles, T., Hahn, N., de Wit, R., Bajorin, D., Ellison, M.C., Frenkl, T., Keefe, S.M., Vuky, J. |
|---|---|
| Zdroj: | In Annals of Oncology September 2017 28 Supplement 5:v301-v301 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|